

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)



(10) International Publication Number
WO 2021/219482 A1

(51) International Patent Classification:
A61L 2/14 (2006.01)

(21) International Application Number:
PCT/EP2021/060502

(22) International Filing Date:
22 April 2021 (22.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2006384.8 30 April 2020 (30.04.2020) GB

(71) Applicant: **CREO MEDICAL LIMITED** [GB/GB]; Creo House Unit 2, Beaufort Park, Beaufort Park Way, Chepstow, Monmouthshire South Wales NP16 5UH (GB).

(72) Inventors: **HANCOCK, Christopher**; Creo House Unit 2, Beaufort Park, Beaufort Park Way, Chepstow, Monmouthshire South Wales NP16 5UH (GB). **TURNER, Louis**; Creo House Unit 2, Beaufort Park, Beaufort Park Way, Chepstow, Monmouthshire South Wales NP16 5UH (GB). **PRESTON, Shaun**; Creo House Unit 2, Beaufort Park, Beaufort Park Way, Chepstow, Monmouthshire South Wales NP16 5UH (GB). **MEADOWCROFT, Simon**; Creo House Unit 2, Beaufort Park, Beaufort Park Way, Chepstow, Monmouthshire South Wales NP16 5UH (GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: STERILISATION APPARATUS FOR PRODUCING PLASMA AND HYDROXYL RADICALS




FIG. 2

(57) Abstract: The invention relates to sterilisation systems suitable for clinical use, e.g. on the human body, medical apparatuses, or hospital bed spaces. In particular, a sterilisation device is provided for generating a flow of hydroxyl radicals, the sterilisation device comprising: a coaxial transmission line, the coaxial transmission line extending in a longitudinal direction and comprising an inner conductor and an outer conductor located around and spaced away from the inner conductor; an end cap mounted on a distal end of the coaxial transmission line, wherein the end cap comprises a distally facing outlet aperture; a fluid conduit extending in the longitudinal direction from a fluid inlet at a distal end of the coaxial transmission line through the end cap to the outlet aperture; and a plasma generating region at a proximal end of the outlet aperture, wherein the plasma generating region contains a first electrode that is electrically connected to the inner conductor, and a second electrode that is electrically connected to the outer conductor, wherein the fluid conduit defines a longitudinal fluid flow path through the device that is aligned with a feed direction in which fluid is receivable through the fluid inlet, and wherein the first electrode and second electrode oppose each other in a transverse direction across the longitudinal fluid flow path in the plasma generating region.

WO 2021/219482 A1

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*